Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Whellan, David

< Back

Profile

djw150

David J. Whellan, MD, MHS, FACC, FAHA

Contact Dr. Whellan

925 Chestnut Street
Mezzanine
Philadelphia, PA 19107

(215) 955-2636
(215) 503-7420 fax

Medical School

MD, Washington University School of Medicine
Master Health Science in Clinical Research, Duke University

Residency

Hospital of University of Pennsylvania (HUP)

Fellowship

Clinical Cardiology, Duke University Medical Center

Board Certification

Internal Medicine
Cardiovascular Disease

Hospital Appointment

Thomas Jefferson University Hospital

Expertise & Research Interests

Dr. Whellan is the Co-Principal Investigator of the HF-ACTION study, a NIH grant for research in heart failure and exercise training. In addition, he has served as the national PI for the PARTNERS HF study and currently sits on the steering committee for the ASCEND and TRACER-ACS trials.

He has authored over 100 peer-reviewed articles, reviews, abstracts, and book chapters on cardiomyopathy; and is an associate editor for American Heart Journal.

Publications

Most Recent Peer-Reviewed Publications

  1. Lessons learned from a clinical trial: Design, rationale, and insights from The Cardiovascular Improvements with Minute Ventilation-targeted Adaptive Sero-Ventilation (ASV) Therapy in Heart Failure (CAT-HF) Study
  2. Proton pump inhibitors and hypomagnesemia in patients with arrhythmias
  3. Erratum: Corrigendum to exercise training for chronic heart failure (ExTraMATCH II): Protocol for an individual participant data meta-analysis (Int J Cardiol. (2014) 174:3 (683-687) DOI: http://dx.doi.org/10.1016/j.ijcard.2014.04.203)
  4. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction. Results From the HF-ACTION Trial
  5. Exercise training and pacing status in patients with heart failure: Results from HF-ACTION
  6. Prognostic Significance of Depression in Blacks with Heart Failure: Insights from Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training
  7. Evaluation of the incremental prognostic utility of increasingly complex testing in chronic heart failure
  8. Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with heart failure
  9. Team-Based Care for Managing Cardiac Comorbidities in Heart Failure
  10. Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations from the Heart Failure Society of America Guideline Committee
  11. Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)
  12. Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure
  13. Photoplethysmographic Signal to Screen Sleep-Disordered Breathing in Hospitalized Heart Failure Patients: Feasibility of a Prospective Clinical Pathway
  14. Authorship in a multicenter clinical trial: The heart failure - A controlled trial investigating outcomes of exercise training (HF-ACTION) authorship and publication (HAP) scoring system results
  15. Stratifying patients at the risk of heart failure hospitalization using existing device diagnostic thresholds
  16. Exercise training as therapy for heart failure current status and future directions
  17. Advanced (stage D) heart failure: A statement from the heart failure society of america guidelines committee
  18. Safety and efficacy of aerobic training in patients with cancer who have heart failure: An analysis of the HF-ACTION randomized trial
  19. Exercise training for chronic heart failure (ExTraMATCH II): Protocol for an individual participant data meta-analysis
  20. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: Subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)